跳到正文
原文
STAT Pharma 医药频道· Meghana Keshavan·· 2026-09-28AI 评分24

AbbVie帕金森病口服药获FDA批准

STAT+: AbbVie wins FDA nod for Parkinson’s pill

AI 导读

AbbVie的帕金森病口服药物获得美国食品药品监督管理局(FDA)批准。原文未提及具体药名、适应症细分或临床试验数据细节,仅确认监管机构动作。

正文

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

This newsletter was composed from a pediatric emergency department. Hot tip, all: Don’t jump off 6-foot playground equipment. You will scare your mother, and wind up in a cast.

The need-to-know this morning

  • Kodiak Sciences said Zenkuda, its experimental vision-sparing treatment for a common cause of age-related blindness, achieved statistical equivalence to Eylea, a standard therapy, in a Phase 3 clinical trial. 
  • Merck said it paid $400 million upfront to China’s SciBrunch Therapeutics, for global license rights to a preclinical cancer drug that targets tumors with KRAS G12D mutations. The deal is valued at $2.13 billion if all future milestones are achieved. 

Novo turns GLP-1 drugs into consumer products

Novo Nordisk is increasingly marketing its GLP-1 drugs less as treatments for a chronic disease and more as consumer products for people who simply want to lose weight, STAT’s Elaine Chen writes. It’s a shift that comes as insurance coverage for these obesity medicines remains limited.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT Pharma 医药频道 · statnews.com